Breaking News Instant updates and real-time market news.

ATXI

Avenue Therapeutics

$4.95

(0.00%)

07:15
06/03/19
06/03
07:15
06/03/19
07:15

Avenue Therapeutics Phase 3 tramadol study achieves primary, secondary endpoints

Avenue Therapeutics announced that its second pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in sum of pain intensity difference over 24 hours, or SPID24, compared to placebo in patients with postoperative pain following abdominoplasty surgery. In addition, the trial met all of its key secondary endpoints. The study also includes a standard-of-care IV opioid as an active comparator: IV morphine 4 mg. In this study, IV tramadol also demonstrated similar efficacy and safety to that of IV morphine. The Phase 3 multicenter, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of IV tramadol in 370 patients following abdominoplasty surgery. Patients were randomized in a 3:3:2 ratio to a postoperative regimen of 50 mg of IV tramadol, placebo, or 4 mg of IV morphine at hours 0, 2, 4 and once every 4 hours thereafter, respectively, for up to 13 doses over the course of 48 hours. Morphine, a standard-of-care analgesic, was included to obtain comparative safety data versus IV Tramadol. The primary efficacy endpoint of the study assessed the analgesic efficacy of IV tramadol compared to placebo as measured by SPID24. The key secondary efficacy endpoints included Patient Global Assessment at 24 hours, SPID48, and total consumption of rescue medicine through 24 hours. A key safety objective of the study was to compare the safety and tolerability of IV tramadol to IV morphine. IV tramadol 50 mg achieved the primary endpoint of statistically superior improvement in pain relief as measured by the SPID24 compared to placebo, as well as met all three key secondary endpoints. IV tramadol and IV morphine demonstrated similar efficacy benefits in the study. IV tramadol was well-tolerated with no drug-related serious adverse events in the trial. Most adverse events were mild or moderate with only 2 patients experiencing a Grade 3 event.

  • 19

    Jun

ATXI Avenue Therapeutics
$4.95

(0.00%)

06/25/18
HCWC
06/25/18
INITIATION
Target $11
HCWC
Buy
Avenue Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce initiated Avenue Therapeutics with a Buy rating and $11 price target, stating that its lead candidate, IV Tramadol, would be highly differentiated as the only IV opioid in the U.S. with a DEA Schedule IV if approved.
07/13/18
OPCO
07/13/18
INITIATION
Target $8
OPCO
Outperform
Avenue Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leland Gershell initiated Avenue Therapeutics with an Outperform rating and $8 price target, telling investors that Avenue is an "under-recognized story" whose fundamentals belie its sub-$50M market cap. He believes the stock is very attractive at current levels, despite the next significant milestone being about a year away, and recommends investors use this opportunity to build a position.

TODAY'S FREE FLY STORIES

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:51
11/21/19
11/21
05:51
11/21/19
05:51
Periodicals
TD Ameritrade soars 26% after CNBC says Charles Schwab buyout could come today »

Charles Schwab (SCHW) is…

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

ETFC

E-Trade

$45.88

0.88 (1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 22

    Nov

SPWR

SunPower

$7.41

-1.12 (-13.13%)

05:49
11/21/19
11/21
05:49
11/21/19
05:49
Syndicate
SunPower 22M share Secondary priced at $7.00 »

Goldman Sachs and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ETFC

E-Trade

$45.88

0.88 (1.96%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:43
11/21/19
11/21
05:43
11/21/19
05:43
Hot Stocks
Breaking Hot Stocks news story on E-Trade, Charles Schwab, TD Ameritrade »

E-Trade drops 16c to…

ETFC

E-Trade

$45.88

0.88 (1.96%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 22

    Nov

KKR

KKR

$29.32

0.21 (0.72%)

05:43
11/21/19
11/21
05:43
11/21/19
05:43
Hot Stocks
KKR to sell LGC to consortium led by Cinven and Astorg, terms not disclosed »

KKR announces it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

, AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

05:43
11/21/19
11/21
05:43
11/21/19
05:43
Hot Stocks
Breaking Hot Stocks news story on Charles Schwab, TD Ameritrade »

Charles Schwab drops 1%…

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:42
11/21/19
11/21
05:42
11/21/19
05:42
Hot Stocks
Breaking Hot Stocks news story on TD Ameritrade, Charles Schwab »

TD Ameritrade jumps 13%…

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

, SCHW

Charles Schwab

$44.74

0.34 (0.77%)

05:41
11/21/19
11/21
05:41
11/21/19
05:41
Periodicals
Charles Schwab in talks to acquire TD Ameritrade, CNBC reports »

Charles Schwab (SCHW) is…

AMTD

TD Ameritrade

$41.39

0.74 (1.82%)

SCHW

Charles Schwab

$44.74

0.34 (0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$189.85

7.64 (4.19%)

05:40
11/21/19
11/21
05:40
11/21/19
05:40
Downgrade
RH rating change  »

RH downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$8.62

-0.03 (-0.35%)

05:39
11/21/19
11/21
05:39
11/21/19
05:39
Downgrade
MacroGenics rating change  »

MacroGenics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

HARP

Harpoon Therapeutics

$14.50

-0.22 (-1.49%)

, ABBV

AbbVie

$87.20

-1.82 (-2.04%)

05:38
11/21/19
11/21
05:38
11/21/19
05:38
Hot Stocks
Harpoon Therapeutics, AbbVie announce licensing, option collaboration »

Harpoon Therapeutics…

HARP

Harpoon Therapeutics

$14.50

-0.22 (-1.49%)

ABBV

AbbVie

$87.20

-1.82 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

THDDY

TV Asahi

$0.00

(0.00%)

05:38
11/21/19
11/21
05:38
11/21/19
05:38
Downgrade
TV Asahi rating change  »

TV Asahi downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

05:37
11/21/19
11/21
05:37
11/21/19
05:37
Downgrade
Nintendo rating change  »

Nintendo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$43.49

-0.33 (-0.75%)

05:36
11/21/19
11/21
05:36
11/21/19
05:36
Earnings
Breaking Earnings news story on Baozun »

Baozun sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SGSOY

SGS SA

$0.00

(0.00%)

05:36
11/21/19
11/21
05:36
11/21/19
05:36
Upgrade
SGS SA rating change  »

SGS SA upgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$43.49

-0.33 (-0.75%)

05:35
11/21/19
11/21
05:35
11/21/19
05:35
Earnings
Baozun reports Q3 EPS 14c, consensus 14c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FUJHY

Subaru

$0.00

(0.00%)

05:35
11/21/19
11/21
05:35
11/21/19
05:35
Downgrade
Subaru rating change  »

Subaru downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$55.27

-0.98 (-1.74%)

05:34
11/21/19
11/21
05:34
11/21/19
05:34
Initiation
Dell Technologies initiated  »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 09

    Dec

  • 09

    Dec

PCG

PG&E

$7.14

0.29 (4.23%)

05:34
11/21/19
11/21
05:34
11/21/19
05:34
Hot Stocks
PG&E begins restoring power in Napa, Sonoma counties »

As of 7 p.m., Pacific Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

DRTGF

Dart Group

$0.00

(0.00%)

05:33
11/21/19
11/21
05:33
11/21/19
05:33
Upgrade
Dart Group rating change  »

Dart Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$2.91

-0.06 (-2.02%)

05:32
11/21/19
11/21
05:32
11/21/19
05:32
Hot Stocks
Cellcom Israel announces purported class action filed against the company »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

TPDKY

Topdanmark

$0.00

(0.00%)

05:31
11/21/19
11/21
05:31
11/21/19
05:31
Upgrade
Topdanmark rating change  »

Topdanmark upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOGL

Golden Ocean

$5.40

0.025 (0.47%)

05:31
11/21/19
11/21
05:31
11/21/19
05:31
Hot Stocks
Golden Ocean announces CEO resignation, chairman Ola Lorentzon named interim CEO »

Golden Ocean announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

05:30
11/21/19
11/21
05:30
11/21/19
05:30
General news
Bond markets erase gains, »

Bond markets erase gains,…

FLNG

Flex LNG

$9.40

0.74 (8.55%)

05:29
11/21/19
11/21
05:29
11/21/19
05:29
Downgrade
Flex LNG rating change  »

Flex LNG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCEXF

Saracen Mineral

$0.00

(0.00%)

05:28
11/21/19
11/21
05:28
11/21/19
05:28
Upgrade
Saracen Mineral rating change  »

Saracen Mineral upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.